Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara 06560, Turkey.
Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa 16059, Turkey.
Future Oncol. 2022 Feb;18(5):533-541. doi: 10.2217/fon-2021-0621. Epub 2021 Nov 26.
The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Patients who were tested negative on the COVID-19 PCR test and those with improved clinical conditions after infection with COVID-19 were enrolled in this study. Patients who received a positive COVID-19 PCR test 28 days after the initial positive PCR test were considered as reinfected. A total of 1024 patients with the diagnosis of solid malignancy and COVID-19 PCR positivity were examined. The reinfection rate was 3.1%. Mortality rate of reinfection was 34.3%. The serum ferritin and creatinine values in reinfection were found to be significantly higher than the first infection (respectively; p = 0.015, p = 0.014). This study has demonstrated one of the first preliminary clinical results of COVID-19 reinfection in solid cancer patients.
本研究旨在评估再次感染 COVID-19 的实体瘤患者的临床和实验室结果。本研究纳入了经 COVID-19 PCR 检测为阴性且感染 COVID-19 后临床状况改善的患者。初次 PCR 检测阳性后 28 天再次 COVID-19 PCR 检测阳性的患者被认为是再感染。共检查了 1024 例确诊为实体恶性肿瘤和 COVID-19 PCR 阳性的患者。再感染率为 3.1%。再感染的死亡率为 34.3%。再感染患者的血清铁蛋白和肌酐值明显高于初次感染（分别为；p = 0.015，p = 0.014）。本研究首次初步展示了实体瘤患者 COVID-19 再感染的临床结果之一。
